Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations.
Regulatory News:
Median Technologies (Paris:ALMDT):
Total number of shares | 18,516,983 |
Number of real voting rights* (excluding treasury shares**) | 18,452,795 |
Theoretical number of voting rights* (including treasury shares**) | 18,493,783 |
(*) Class E preference shares are non-voting
(**) pursuant to article 223-11 of the AMF's General Regulations
About Median Technologies: Pioneering innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241112243576/en/
Contacts:
Median Technologies
Emmanuelle Leygues
VP, Corporate Marketing Financial Communications
+33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com
Press ALIZE RP
Caroline Carmagnol
+33 6 64 18 99 59
median@alizerp.com
Investors ACTIFIN
Ghislaine Gasparetto
+33 6 21 10 49 24
ghislaine.gasparetto@seitosei-actifin.com
